Related references
Note: Only part of the references are listed.Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to
Probir Kumar Ojha et al.
MOLECULAR DIVERSITY (2021)
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
Angel Y. S. Wong et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes
Mina T. Kelleni
BIOMEDICINE & PHARMACOTHERAPY (2021)
Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System
Kathleen M. Andersen et al.
CLINICAL INFECTIOUS DISEASES (2021)
Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy
Parteek Prasher et al.
DRUG DEVELOPMENT RESEARCH (2021)
Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study
Daniele Generali et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia
Jose Francisco Pascual Pareja et al.
MEDICINA CLINICA (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)
Samuel Egieyeh et al.
PLOS ONE (2021)
Efficacy of canakinumab in mild or severe COVID-19 pneumonia
Falasca Katia et al.
IMMUNITY INFLAMMATION AND DISEASE (2021)
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Anthony C. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19
Jungchan Park et al.
SCIENTIFIC REPORTS (2021)
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19
Joht Singh Chandan et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study
Laila Carolina Abu Esba et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression
Matthew E. Grunewald et al.
JOURNAL OF VIROLOGY (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
Yvan Jamilloux et al.
AUTOIMMUNITY REVIEWS (2020)
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
George Dimopoulos et al.
CELL HOST & MICROBE (2020)
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
Wen Zhang et al.
CLINICAL IMMUNOLOGY (2020)
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Chuan Qin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
Junmei Wang
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Lei Fang et al.
LANCET RESPIRATORY MEDICINE (2020)
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon et al.
NATURE (2020)
COVID-19: Immunology and treatment options
Susanna Felsenstein et al.
CLINICAL IMMUNOLOGY (2020)
Ibuprofen use and clinical outcomes in COVID-19 patients
E. Rinott et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Revisiting potential druggable targets againstSARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review
Abdullah Al Mamun Sohag et al.
DRUG DEVELOPMENT RESEARCH (2020)
Severe COVID-19: NLRP3 Inflammasome Dysregulated
Daan F. van den Berg et al.
FRONTIERS IN IMMUNOLOGY (2020)
Targeting the NLRP3 Inflammasome in Severe COVID-19
Tracey L. Freeman et al.
FRONTIERS IN IMMUNOLOGY (2020)
COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status
Tiffany Thomas et al.
JCI INSIGHT (2020)
Off-label therapy targeting pathogenic inflammation in COVID-19
Luigina Romani et al.
CELL DEATH DISCOVERY (2020)
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19
Jeremy K. Y. Yap et al.
JOURNAL OF IMMUNOLOGY (2020)
Cytokine storm induced by SARS-CoV-2
Peipei Song et al.
CLINICA CHIMICA ACTA (2020)
Association Between Prescribed Ibuprofen and Severe COVID-19 Infection: A Nationwide Register-Based Cohort Study
Kristian Kragholm et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19
Raphael Cauchois et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Wei Luo et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Corticosteroids in COVID-19 ARDS Evidence and Hope During the Pandemic
Hallie C. Prescott et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis
Jonathan A. C. Sterne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
Enrique Iglesias-Julian et al.
JOURNAL OF AUTOIMMUNITY (2020)
Drug repurposing approach to fight COVID-19
Thakur Uttam Singh et al.
PHARMACOLOGICAL REPORTS (2020)
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
Sawittree Sahakijpijarn et al.
PHARMACEUTICS (2020)
Role of monoclonal antibody drugs in the treatment of COVID-19
Claudio Ucciferri et al.
WORLD JOURNAL OF CLINICAL CASES (2020)
Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids
Damiano D'Ardes et al.
MICROORGANISMS (2020)
Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 Mpro Protease
Eduardo Tejera et al.
MOLECULES (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
Giulio Cavalli et al.
LANCET RHEUMATOLOGY (2020)
Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space
Joel Kowalewski et al.
HELIYON (2020)
Canakinumab in a subgroup of patients with COVID-19
Claudio Ucciferri et al.
LANCET RHEUMATOLOGY (2020)
Anakinra Therapy for Non-cancer Inflammatory Diseases (vol 9, 1157, 2018)
Giulio Cavalli et al.
FRONTIERS IN PHARMACOLOGY (2019)
Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host
Matae Ahn et al.
NATURE MICROBIOLOGY (2019)
The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses
Remi Rosiere et al.
CANCERS (2019)
The IL-1 family of cytokines and receptors in rheumatic diseases
Charles Anthony Dinarello
NATURE REVIEWS RHEUMATOLOGY (2019)
Tryptophan Dietary Impacts Gut Barrier and Metabolic Diseases
Soraya Taleb
FRONTIERS IN IMMUNOLOGY (2019)
The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease
Veit Rothhammer et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease
Allison Agus et al.
CELL HOST & MICROBE (2018)
Development of Novel Indole-3-Aldehyde-Loaded Gastro-Resistant Spray-Dried Microparticles for Postbiotic Small Intestine Local Delivery
Matteo Puccetti et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis
Matteo Puccetti et al.
MEDIATORS OF INFLAMMATION (2018)
Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals
Fakhrossadat Emami et al.
PHARMACEUTICS (2018)
Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway
Soung-Min Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Biodegradable hydrophilic carriers for the oral delivery of hematological factor IX for hemophilia B treatment
Sarena D. Horava et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis
Rossana G. Iannitti et al.
NATURE COMMUNICATIONS (2016)
The Aryl Hydrocarbon Receptor: Multitasking in the Immune System
Brigitta Stockinger et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
AhR sensing of bacterial pigments regulates antibacterial defence
Pedro Moura-Alves et al.
NATURE (2014)
Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription
Wanwan Huai et al.
NATURE COMMUNICATIONS (2014)
Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Ira Tabas et al.
SCIENCE (2013)
IDO and regulatory T cells:: a role for reverse signalling and non-canonical NF-κB activation
Paolo Puccetti et al.
NATURE REVIEWS IMMUNOLOGY (2007)
IDO and interferon-α-induced depressive symptoms:: a shift in hypothesis from tryptophan depletion to neurotoxicity
MC Wichers et al.
MOLECULAR PSYCHIATRY (2005)
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection
N Schmitz et al.
JOURNAL OF VIROLOGY (2005)
Share Paper
